19-oxo-delta(4) androstene-3,17-dione: RN given refers to unlabeled parent cpd; an estrogen prodrug [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
3,17-dioxoandrost-4-en-19-al : An androstanoid that is androst-4-en-19-al substituted by oxo groups at positions 3 and 17. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 92854 |
| CHEBI ID | 799 |
| SCHEMBL ID | 874927 |
| MeSH ID | M0062441 |
| Synonym |
|---|
| 3,17-dioxoandrost-4-en-19-al |
| 19-oxo-delta(4) androstene-3,17-dione |
| 19-oxoandrostendione |
| 4-androstene-3,17-dione-19-al |
| 19-oxo-androst-4-ene-3,17-dione |
| 19-aldehydo-4-androstene-3,17-dione |
| 19-keto-delta(4) androstene-3,17-dione |
| CHEBI:799 |
| androst-4-en-19-al,17-dioxo- |
| nsc-76985 |
| 19-aldoandrostenedione |
| 968-49-0 |
| nsc76985 |
| 19-oxoandrost-4-ene-3,17-dione |
| C05297 |
| 19-oxoandrostenedione |
| LMST02020083 |
| (8r,9s,10s,13s,14s)-13-methyl-3,17-dioxo-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthrene-10-carbaldehyde |
| A845648 |
| (8r,9s,10s,13s,14s)-13-methyl-3,17-dioxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthrene-10-carbaldehyde |
| 19-oxoandro-4-stene-3,17-dione |
| androst-4-en-19-al, 3,17-dioxo- |
| nsc 76985 |
| unii-x07f7694nw |
| x07f7694nw , |
| 4-androsten-19-al-3,17-dione |
| SCHEMBL874927 |
| androstenedione, 19-aldehyde |
| 3,17-dioxoandrost-4en-19-al |
| XRCFMDPVHKVRDJ-BGJMDTOESA-N |
| DTXSID00242509 |
| 4-androsten-3,17-dione 19-aldehyde |
| Q27105362 |
| (3as,3br,9as,9bs,11as)-11a-methyl-1,7-dioxo-1h,2h,3h,3ah,3bh,4h,5h,7h,8h,9h,9ah,9bh,10h,11h,11ah-cyclopenta[a]phenanthrene-9a-carbaldehyde |
| Role | Description |
|---|---|
| human metabolite | Any mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens). |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| 17-oxo steroid | Any oxo steroid carrying the oxo group at position 17. |
| 19-oxo steroid | |
| androstanoid | Any steroid based on an androstane skeleton and its derivatives. |
| steroid aldehyde | Any steroid substituted by a formyl group. |
| 3-oxo-Delta(4) steroid | A 3-oxo steroid conjugated to a C=C double bond at the alpha,beta position. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Pathway | Proteins | Compounds |
|---|---|---|
| estradiol biosynthesis I | 5 | 9 |
| estradiol biosynthesis I (via estrone) | 2 | 9 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 8 (66.67) | 18.7374 |
| 1990's | 3 (25.00) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 14 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||